4-carbamoyl-4-(4-chloro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester | 849106-03-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-carbamoyl-4-(4-chloro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-carbamoyl-4-(4-chlorophenyl)piperidine-1-carboxylate；N-Boc-4-(p-chlorophenyl)-piperidine-4-carbamide
• CAS: 849106-03-2
• 化学式: C₁₇H₂₃ClN₂O₃
• 分子量: 338.834
• InChiKey: YPANXJLTQBPMBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-carbamoyl-4-(4-chloro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 生成 4-(4-chloro-phenyl)-piperidine-4-carboxylic acid amide
  参考文献：
  名称：

  Chemokine receptor antagonists and methods of use thereof

  摘要：

  揭示了新化合物和一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用由以下公式（1）表示的化合物或其生理上可接受的盐的有效量。

  公开号：

  US20050070549A1
• 作为产物：
  描述：

  N,N-双(2-氯乙基)氨基甲酸叔丁酯 在 水 、 sodium hydride 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 18.0h， 生成 4-carbamoyl-4-(4-chloro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

  摘要：

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。

  公开号：

  US20160031908A1

文献信息

• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。
• [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases
  申请人：Rice Ken

  公开号：US20080188482A1

  公开（公告）日：2008-08-07

  The invention provides compounds of formula (I) and methods for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

  本发明提供了式（I）的化合物和抑制激酶的方法，更具体地是p70S6激酶，更优选的是p70S6，Akt-1和Akt-2激酶的抑制剂。本发明提供了用于调节蛋白激酶酶活性以调节细胞活动（如增殖，分化，程序性细胞死亡，迁移，化学入侵和代谢）的化合物。本发明的化合物抑制，调节和/或调节与上述细胞活动变化相关的激酶受体信号转导途径，本发明包括含有这些化合物的组合物和使用它们治疗依赖于激酶的疾病和情况的方法。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
  申请人：Luly Jay R.

  公开号：US20090281081A1

  公开（公告）日：2009-11-12

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  本发明涉及新化合物以及一种治疗与异常白细胞招募和/或激活相关的疾病的方法。该方法包括向需要治疗的受体内给予一种有效量的化合物，该化合物表示为：或其生理上可接受的盐。
• Chemokine receptor antagonists and methods of use therefor
  申请人：Luly R. Jay

  公开号：US20070060592A1

  公开（公告）日：2007-03-15

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  本发明涉及一种新型化合物和一种治疗与异常白细胞招募和/或激活相关的疾病的方法。该方法包括向需要治疗的受体内投与有效量的化合物，所述化合物的表示式为：或其生理上可接受的盐。
• HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF
  申请人：Zhejiang Hisun Pharmaceutical Co., Ltd.

  公开号：EP4092019A1

  公开（公告）日：2022-11-23

  The present invention relates to heteroaryl derivatives, preparation methods therefor, and applications thereof in medicine. Specifically, the present invention relates to a heteroaryl derivative represented by general formula (AI), a preparation method therefor, and a pharmaceutically acceptable salt, and use thereof as a therapeutic agent, in partucular, as an SHP2 allosteric inhibitor, wherein the definition of substituents in general formula (AI) is the same as that in the description.

  本发明涉及杂环芳基衍生物、其制备方法和在医学上的应用。具体地，本发明涉及一种由通式（AI）表示的杂环芳基衍生物、其制备方法、药学上可接受的盐以及作为治疗剂的用途，特别是作为SHP2变构抑制剂，其中通式（AI）中取代基的定义与描述中相同。